吡格列酮对非酒精性脂肪肝的疗效观察

Safety and effectiveness of pioglitazone in the treatment of non-alcoholic fatty liver disease

目的寻找一安全有效的治疗非酒精性脂肪性肝病的方法。方法将非酒精性脂肪性肝病患者43例随机分组,吡格列酮组22例(n=22),对照组21例(n=21),比较两组疗效(观察ALT,GGT,TG,HOMA-IR,BMI等指标)。结果3个月时,两组的观察指标均有改善,虽治疗组更明显,但无显著差异(P>0.05),6个月时,ALT,GGT,TG,HOMA-IR及疗效,治疗组与对比组比较,疗效有显著差异(19/22,11/21,P<0.05)。结论胰岛素增敏剂(吡格列酮)治疗NAFLD,安全、有效,值得临床推广应用。

Objective To find out a safe and effective treatment of non - alcoholic fatty liver disease （NAFLD） ; Methods 43 cases of NAFLD were randomized divided into tow group; pioglitazone group （n = 22 ） and control group （n =21 ）, ALT, GGT, TG, HOMA - IR, BMI were compared between the two group. Results At the end of the 3rd month, the parameters were all improved, but have no statistical difference. （P 〉0. 05） ; At the end of the 6th months, ALT, GGT, TG, HOMA - IR and effectiveness in pioglitazone group were much better than that in the control ; the differences were significant （ P 〈 0. 05 ）. Conclusion Pioglitazone is safe and effective in the treatment of NAFLD.